Latest Symphogen A/S Stories
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
Gallus BioPharmaceuticals, LLC, a premier pure-play biologics contract manufacturing organization has signed a manufacturing agreement with Symphogen, A/S, a private biopharmaceutical company
COPENHAGEN, Denmark, January 14, 2014 /PRNewswire/ -- Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic
COPENHAGEN, Denmark and STOCKHOLM, Sweden- July 16, 2008.
- A woman chauffeur.
- A woman who operates an automobile.